After last month’s flurry of transactions, business calmed down as it often does during the start of summer. Here are the key deals and trends from mid-June through the third week of … [Read more...]

Mid-May to mid-June was the busiest period of the year for diagnostic deal making in terms of both volume and magnitude. Here is a look at the highlights. M&A Dollar value-wise, the biggest lab … [Read more...]

The pace of deal making has picked up a bit, but deal volume remains relatively low on both the M&A and strategic alliance fronts. As usual, smaller molecular and genomics firms are supplying … [Read more...]

While M&A activity in the wider healthcare industry is heating up deal making in the diagnostics space remains relatively light, not so much in terms of volume but in size, at least compared to … [Read more...]

Based on the early returns, the market analysts that predicted 2018 would see a slowdown in strategic Dx deal making appear to be right. But while deal volume was low on both the M&A and alliance … [Read more...]

As the calendar turned to 2018 and Medicare turned to PAMA, diagnostic deal making revved up. Deal volume was relatively heavy although short on drama. But what looks to be a big year is just … [Read more...]

Good news for any of you who slept through December 2017: You didn't miss much—at least as far as blockbuster strategic deals in the clinical laboratory space are concerned. M&AIn contrast to … [Read more...]